Rare Daily Staff
The Japanese biopharmaceutical company AnGes has acquired the next-generation gene editing company EmendoBio at a valuation of $250 million.
EmendoBio will operate as an independent wholly owned subsidiary of AnGes and will continue to maintain its business operations at its facilities in New York and Tel Aviv, Israel. The acquisition was completed on December 15, 2020.
EmendoBio is pioneering its OMNI technologies, a next-generation novel nuclease discovery platform and a nuclease optimization platform that incorporate protein engineering and directed evolution capabilities. The company said its technology enables previously undemonstrated high levels of precision gene editing and target specific optimization to make any gene targetable, unlocking a way to treat a broad range of genetic diseases including many previously considered untreatable.
“The alliance with AnGes brings new resources and synergies to our operations that will accelerate product development, partnerships and commercial opportunities in the years ahead,” said David Baram, president and CEO of EmendoBio.
The acquisition will allow AnGes to expand its pipeline and partnerships and introduce gene editing capabilities by leveraging EmendoBio’s proprietary platforms, scientists, researchers, and relationships with academic collaborators and scientific advisors.
Photo: David Baram, president and CEO of EmendoBio
Stay Connected
Sign up for updates straight to your inbox.